Literature DB >> 7439991

Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.

R C Humphres, P R Henika, R W Ferraresi, J L Krahenbuhl.   

Abstract

Studies were carried out to determine whether treatment of mice with the synthetic adjuvant muramyl dipeptide (MDP) afforded any resistance to infection with Listeria monocytogenes. Regardless of the timing, dose, or route of administration, there was no evidence that treatment with either MDP or two of its analogs (des-MDP or MDP-D-D) induced any resistance to listeria infection in BALB/c, CBA/J, or C57BL/6J mice. In contrast, pretreatment with MDP induced marked protection to infection with Streptococcus pneumoniae (type III).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439991      PMCID: PMC551335          DOI: 10.1128/iai.30.2.462-466.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Modulation of the immune response by a synthetic adjuvant and analogs.

Authors:  L Chedid; F Audibert; P Lefrancier; J Choay; E Lederer
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

2.  Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components.

Authors:  F Audibert; L Chédid; P Lefrancier; J Choay
Journal:  Cell Immunol       Date:  1976-02       Impact factor: 4.868

3.  Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  C Merser; P Sinay; A Adam
Journal:  Biochem Biophys Res Commun       Date:  1975-10-27       Impact factor: 3.575

4.  Target cells for the activity of a synthetic adjuvant: muramyl dipeptide.

Authors:  I Löwy; C Bona; L Chedid
Journal:  Cell Immunol       Date:  1977-03-01       Impact factor: 4.868

5.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

6.  Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.

Authors:  L Chedid; M Parant; F Parant; P Lefrancher; J Choay; E Lederer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

7.  Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds.

Authors:  I Azuma; K Sugimura; T Taniyama; M Yamawaki; Y Yamamura
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

8.  Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants.

Authors:  D Juy; L Chedid
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

9.  The influence of immunologically committed lymphoid cells on macrophage activity in vivo.

Authors:  G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

10.  Cellular kinetics associated with the development of acquired cellular resistance.

Authors:  R J North
Journal:  J Exp Med       Date:  1969-08-01       Impact factor: 14.307

View more
  9 in total

1.  Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.

Authors:  J L Krahenbuhl; S D Sharma; R W Ferraresi; J S Remington
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

2.  Effect of free or liposome-encapsulated muramyl dipeptide on uptake and intracellular survival of Listeria monocytogenes in mouse peritoneal macrophages in vitro.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

3.  Effects of muramyl dipeptide on superoxide anion release and on anti-microbial activity of human macrophages.

Authors:  C B Wilson; J Bohnsack; W M Weaver
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

4.  Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice.

Authors:  N C Phillips; L Chedid
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

5.  New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP.

Authors:  L Chedid; F Audibert
Journal:  Springer Semin Immunopathol       Date:  1985

6.  Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.

Authors:  E B Fraser-Smith; T R Matthews
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

Review 7.  Alteration of non-specific resistance to infection with Listeria monocytogenes.

Authors:  C H Wirsing von König; B Heymer; H Finger; P Emmerling; H Hof
Journal:  Infection       Date:  1988       Impact factor: 3.553

8.  Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice.

Authors:  E B Fraser-Smith; R V Waters; T R Matthews
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

9.  Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections.

Authors:  Y Osada; M Mitsuyama; T Une; K Matsumoto; T Otani; M Satoh; H Ogawa; K Nomoto
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.